UNITEDHEALTH GROUP INC

UNH· FY2025 10-K· Analyzed 1 mo ago
PASS
Growth Rates — CAGR from SEC 10-K XBRL filings
Revenue
11.0%
FY2015–2025
Net Income
7.6%
FY2015–2025
Free Cash Flow
7.0%
FY2015–2025
EPS (Diluted)
8.2%
FY2015–2025
Latest Metrics — FY2025 · SEC XBRL
Return on Equity
12.0%
NI ÷ Equity
Return on Assets
3.9%
NI ÷ Assets
Net Profit Margin
2.7%
NI ÷ Revenue
Debt / Equity
0.72x
LT Debt ÷ Equity
Intrinsic Value Estimate — DCF (10% discount · 3% terminal · FCF growth capped 15%)
Total Business Value
$249.0B
Per Share (approx.)
$274.86
25% Margin of Safety
$206.15
Conservative entry
50% Margin of Safety
$137.43
Buffett's ideal entry
Growth Rate Used
7.7%
Latest FCF
$12.0B

Berkshire requires a 25–50% discount to intrinsic value before buying.

Buffett Quality Checklist
ROE >15% consistently (≥7 of last 10 years)
Free cash flow positive (≥8 of last 10 years)
Conservative leverage — Debt/Equity below 1
Revenue growing at CAGR >5%
EPS growing at CAGR >5%
10-Year Financial History — SEC EDGAR 10-K Filings
YearRevenueNet IncomeFCFOwner EarningsROENet MarginLT DebtCash
2016$184.8B$7.0B$8.1B$7.4B18.4%3.8%$25.8B$10.4B
2017$201.2B$10.6B$11.6B$10.8B21.2%5.2%$28.8B$12.0B
2018$226.2B$12.0B$13.7B$12.4B22.1%5.3%$34.6B$10.9B
2019$242.2B$13.8B$16.4B$14.5B22.9%5.7%$36.8B$11.0B
2020$257.1B$15.4B$20.1B$16.2B22.5%6.0%$38.6B$16.9B
2021$287.6B$17.3B$19.9B$17.9B23.0%6.0%$42.4B$21.4B
2022$324.2B$20.1B$23.4B$20.7B24.7%6.2%$54.5B$23.4B
2023$371.6B$22.4B$25.7B$23.0B23.7%6.0%$58.3B$25.4B
2024$400.3B$14.4B$20.7B$15.0B14.7%3.6%$72.4B$25.3B
2025$447.6B$12.1B$16.1B$12.8B12.0%2.7%$72.3B$24.4B
Warren & Charlie
Buffett / Munger — quality, moat & valuation

UNITEDHEALTH GROUP INC (UNH) — Investment Memo

🐂 The Bull Case (Warren's voice)

  • The Toll Booth Advantage: UNH has achieved the holy grail of financial services: they capture the premium on the front end and the expense on the back end. This vertical integration creates a "feedback loop" of data that no competitor can touch.
  • Data as a Moat: With access to longitudinal data for millions of patients, their ability to price risk and manage care pathways is unparalleled. In a business where actuarial science is the only defense, they have the best set of keys to the vault.
  • Optum’s Scale: Optum is not just an add-on; it is the infrastructure of the American healthcare system. As long as the US spends 18% of its GDP on healthcare, UNH is the primary administrator of that transaction.
  • The Price of Entry: We would only consider this when the market punishes the stock for temporary regulatory noise, bringing the price down to levels where the yield on the "float" and the recurring revenue of Optum provide a significant cushion.

🐻 The Bear Case (Charlie inverts)

Munger's rule: "Show me where I'll die and I won't go there."

  • The "Too Big" Trap: The business has become a political lightning rod. When you own the insurance carrier and the doctor’s office, you are the entire supply chain. That is not a business; that is a target for populist legislation. If the government decides to break up this "vertical monopoly," the equity value will crater instantly.
  • Complexity-Induced Blindness: The management is now running an enterprise so complex that it is fundamentally unmanageable. The fact that they are selling more to earn less ($447.6B revenue vs. $12.1B net income) proves the bureaucracy is eating the margins. They have reached the point of "diseconomies of scale."
  • The Debt Poison: Loading up on $72.3B of debt while earnings are contracting is the behavior of a business fighting for its life, not a business compounding its way to greatness. They are financing a shrinking return on capital with borrowed money. It ends in a liquidity crunch.

💰 Valuation & Margin of Safety

Based on our DCF estimates and the current degradation of operating leverage:

  • Intrinsic value estimate: $274.86 per share.
  • 25% margin of safety entry: $206.15 (Conservative).
  • 50% margin of safety entry: $137.43 (Buffett's ideal).

Status: The market is currently pricing this for a growth miracle that the financial statements—specifically the collapsing Net Income—refute. It is grossly expensive.

Verdict: PASS

The business is currently caught in a death spiral of rising revenue and collapsing margins, which suggests the underlying model is fundamentally broken. We do not pay premium prices for "toll booths" that are rapidly losing their ability to collect a profit. Until the capital allocation improves and the operating bloat is purged, there is no margin of safety here.

Other Analyst Views· Lynch · Damodaran
Research Notes· Money Model · Moat · Financials · Management

Data sourced from SEC EDGAR XBRL filings (10-K only). For educational purposes — not investment advice.